论文部分内容阅读
目的评价奥沙利铂联合5-氟尿嘧啶治疗中晚期食管癌的临床疗效及安全性。方法将65例局部中晚期不能手术的食管癌患者随机分为对照组32例和试验组33例。2组患者均予以常规分割放疗,每次2.0 Gy,总剂量56~66Gy。化疗在放疗的第1天开始,对照组予以52.5 mg·m~(-2)·d~(-1)顺铂,静脉滴注,第1天+500 mg·m~(-2)·d~(-1)5-氟尿嘧啶,静脉滴注,第1~5天;试验组予以奥沙利铂85~100 mg·m~(-2)·d~(-1),静脉滴注2 h,第1天+500 mg·m~(-2)·d~(-1)5-氟尿嘧啶,静脉滴注,第1~5天。2组患者一个疗程均为4周,共治疗2个疗程。比较2组患者的临床疗效和不良反应发生率。结果治疗后,试验组和对照组的总有效率分别为81.80%和75.00%(P>0.05),疾病控制率分别为96.97%和93.75%(P>0.05),1年的生存率分别为77.30%和68.20%(P>0.05)。试验组的恶心呕吐发生率为36.40%显著低于对照组62.50%(P<0.05);试验组的感觉异常发生率为24.00%显著高于对照组的0(P<0.05)。结论奥沙利铂联合5-氟尿嘧啶同步放化疗治疗中晚期食管癌的近期临床疗效确切,不良反应可控。
Objective To evaluate the clinical efficacy and safety of oxaliplatin plus 5-fluorouracil in the treatment of advanced esophageal cancer. Methods Sixty-five patients with locally advanced esophageal cancer were randomly divided into control group (32 cases) and experimental group (33 cases). The patients in both groups were given conventional fractionated radiotherapy at a dose of 2.0 Gy with a total dose of 56 Gy to 66 Gy. Chemotherapy was started on the first day of radiotherapy, while the control group was treated with cisplatin (52.5 mg · m -2 · d -1) intravenously, on the first day +500 mg · m -2 · d ~ (-1) 5-Fluorouracil for 1 to 5 days. The test group received oxaliplatin 85 ~ 100 mg · m ~ (-2) · d ~ (-1) intravenously for 2 h , On the first day +500 mg · m -2 (-2) · d -1 5-fluorouracil, intravenous drip, the first 5 days. Two groups of patients with a course of 4 weeks, a total of 2 courses of treatment. The clinical efficacy and incidence of adverse reactions in two groups were compared. Results After treatment, the total effective rates were 81.80% and 75.00% in the test group and control group, respectively. The disease control rates were 96.97% and 93.75% respectively (P> 0.05), and the 1-year survival rates were 77.30 % And 68.20% (P> 0.05). The incidence of nausea and vomiting in the experimental group was significantly lower than that in the control group (36.40%, 62.50%, P <0.05). The incidence of sensory abnormality in the experimental group was significantly higher than that in the control group (24.00%, P <0.05). Conclusion Oxaliplatin combined with 5-fluorouracil concurrent chemoradiotherapy in the treatment of advanced esophageal cancer clinical efficacy of the exact recent adverse reactions can be controlled.